Oxford’s COVID-19 vaccine ‘highly effective,’ trials show

A COVID-19 vaccine being developed by the University of Oxford and British pharmaceutical company AstraZeneca was found to have an average efficacy rate of 70 percent following a large-scale trial.

The trial involved two separate dosing regimens, one which showed a 90 percent efficacy rate, and the other with 62 percent.

Professor Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said the results “show that we have an effective vaccine that will save many lives.”

Today marks an important milestone in the fight against #COVID19. Interim data show the #OxfordVaccine is 70.4% effective, & tests on two dose regimens show that it could be 90%, moving us one step closer to supplying it at low cost around the world>> https://t.co/fnHnKSqftT pic.twitter.com/2KYXPxFNz1
— University of Oxford (@UniofOxford) November 23, 2020

The Oxford vaccine is said to be cheaper, requires simpler storage and is easier to transport than those developed by Pfizer and Moderna.

Clark Kent

Clark Kent came to the city of Metropolis to study journalism at Metropolis University. After graduation, Clark took a job at the Daily Planet as a reporter. Under the direction of editor-in-chief Perry White, he quickly gained a reputation as a journalist who was unafraid to cover the injustices of the city, including its political corruption .